No. of participants | Mean age, yr | Clinical data | Methodological aspects | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Study | Patients/men | Controls/men | Patients | Controls | Diagnosis | Illness duration, mo | PANSS, T/P/N | Intensity | Slice thickness, mm | FWHM, mm | Correction step | Quality scores |
Salgado-Pineda et al37 | 13/13 | 13/13 | 23.76 | 23.36 | FES | NA | NA/NA/NA | 1.5 T | 1 | 8 | No | 10.5 |
Jayakumar et al38 | 18/9 | 18/9 | 24.90 | 25.70 | FES | 10.30 | 79.00/19.00/23.00 | 1.5 T | 1 | 12 | Yes | 12 |
Prasad et al39 | 15/NA | 12/NA | NA | NA | FES | 27.80 | NA/NA/NA | 1.5 T | 1.5 | 12 | No | 10.5 |
Chua et al40 | 26/12 | 38/18 | 32.00 | 33.00 | FES | 4.00 | 72.00/NA/NA | 1.5 T | 3 | 4.4 | Na | 10.5 |
Meda et al41 | 22/14 | 21/13 | 25.09 | 26.24 | SCZ | NA | NA/NA/NA | 1.5 T | 1.5 | 8 | Yes | 11.5 |
Witthaus et al42 | 23/16 | 29/17 | 26.40 | 25.70 | FES | NA | NA/19.30/18.00 | 1.5 T | 1 | 12 | Yes | 11.5 |
Venkatasubramanian et al43 | 30/21 | 27/9 | 30.10 | 27.40 | FES | 41.70 | NA/22.00/23.00 | 1.5 T | 1 | 12 | Yes | 12 |
Berge et al44 | 21/12 | 20/8 | 24.81 | 25.30 | FES | NA | 84.43/26.19/17.48 | NA | 1.4 | 8 | No | 9.5 |
Suazo et al45* | 17/10 | 13/10 | 33.29 | 30.92 | 10, FES | 63.30 | 74.20/20.93/16.53 | 1.5 T | 1.5 | NA | No | 11 |
Ren et al31 | 100/41 | 100/41 | 24.30 | 24.39 | FES | 6.25 | 97.88/25.11/18.84 | 3.0 T | 1 | 6 | Yes | 12 |
Guo et al28 (1)† | 27/16 | 30/16 | 25.10 | 25.60 | SCZ | 1.66 | 73.70/24.30/13.80 | 1.5 T | 1.8 | 8 | Yes | 12 |
Guo et al28 (2) | 30/16 | 30/16 | 25.70 | 25.60 | SCZ | 14.05 | 75.30/23.00/16.00 | 1.5 T | 1.8 | 8 | Yes | 12 |
Guo et al34 | 49/30 | 50/23 | 22.69 | 23.48 | FES | 22.45 | 91.31/22.27/22.82 | 3.0 T | 1 | 8 | Yes | 12 |
Guo et al46 | 51/33 | 41/24 | 22.50 | 22.80 | FES | 8.40 | 91.30/22.80/22.40 | 3.0 T | 1.1 | 8 | Yes | 12 |
Nenadic et al47 | 24/12 | 49/23 | 24.90 | 23.80 | FES | 4.10 | 53.20/30.40/29.10 | 3.0 T | 1 | 12 | No | 11 |
Yue et al48 | 20/10 | 24/13 | 24.45 | 24.79 | FES | 22.92 | 88.95/21.25/19.10 | 3.0 T | 1 | 8 | No | 11 |
FES = first-episode schizophrenia; FWHM = full width at half maximum; N = negative; NA = not available; P = positive; PANSS = Positive And Negative Syndrome Scale; SCZ = schizophrenia; T = total.
↵* All patients included in the structural studies were drug-free except for those in this study, who underwent a medication wash-out period of longer than 1 month.
↵† This study divided patients into 2 data sets according to different duration of illness.